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Introduction Immunotherapy has shown efficacy in the treatment of different malignancies. Nivolumab, an 
immune checkpoint inhibitor directed against PD-1, has been approved for Non Small Cell Lung Cancer 
(NSCLC) in pretreated patients. Although it is generally well tolerated, immunotherapy may be complicated 
by a wide range of immune-mediated adverse events. Herein we describe the case of an uncommon skin 
toxicity arising as alopecia universalis, induced by nivolumab in a patient with NSCLC. 
Case description A 61-year-old man received nivolumab for metastatic NSCLC after progression to 3 lines 
of chemotherapy. The treatment was prescribed in June 2016, and induced a rapid and significant disease 
response. Nivolumab was well tolerated until May 2017, when a partial alopecia at hair and eyelashes 
appeared. In the next months, alopecia became complete and extended to the whole body surface. The 
dermatologic picture was compatible with alopecia areata. A topical steroid therapy was attempted, without 
benefit. The patient refused systemic treatments and is still undergoing nivolumab, without new toxicities and 
with persistent disease response. 
Conclusions This case suggests that alopecia areata may be a rare immune-related adverse event of 
immune checkpoint agents. Its late onset in our patient is very uncommon and unexpected, underlining that 
the risk of nivolumab-induced toxicity is not limited to the beginning of treatment. Though its rarity, alopecia 
areata should be considered in the range of adverse events potentially induced by immune checkpoint 
inhibitors even in the long term. Potential association between toxicity and efficacy of immunotherapy in 
NSCLC warrants further investigation. 
 











Immune Checkpoint Inhibitors (ICIs) are a class of anti-cancer drugs  that stimulate immune response 
towards neoplastic cells through different molecular mechanisms. Nivolumab is a fully-human IgG4 
monoclonal antibody, which binds Programmed Death-1 (PD-1) expressed on T-lymphocytes. Hence it 
blocks its interaction with Programmed Death Ligand-1 (PD-L1) physiologically present on antigen-
presenting cells, but also on tumor cells. The complex PD-1/PD-L1 has an inhibitory effect on T-lymphocytes 
and is a crucial mechanism through which tumor cells escape immune surveillance. In recent years, the 
efficacy of nivolumab has been proved in the treatment of different malignancies, such as melanoma, lung 
cancer, head and neck cancer.1 In particular, this drug has been approved for the treatment of metastatic 
Non Small Cell Lung Cancer (NSCLC) in second or more advanced lines of therapy, irrespective of PD-L1 
expression.2 All ICIs can induce immune-related adverse events (AEs) potentially affecting various organs, 
with different grades of severity and time of insurgence. Skin toxicity is infrequent and generally limited to 
pruritus, erythematous rash and less commonly vitiligo. The onset of dermatologic AEs is often quite early 
and their grade of severity is usually mild to moderate.3 Herein we report a particularly uncommon 
manifestation of delayed skin toxicity, associated to an exceptional disease response, in a patient with 
advanced NSCLC receiving nivolumab. We precise that the patient provided written informed consent for the 
publication of his case.   
Case description 
EB, a Caucasian male, was born in March 1956 and was a current smoker of 30 pack-year. His medical 
history was unremarkable and he did not assume any chronic therapy. In December 2014, he was 
diagnosed with right lung adenocarcinoma extended to mediastinal nodes, with an isolated right cerebellar 
lesion determining compression of the fourth ventricle. Due to neurologic symptoms, he received 
radiosurgery (12 Gy in single fraction) soon after diagnosis, with complete neurologic recovery. Then he was 
treated with two cycles of chemotherapy with cisplatin 75 mg/sm i.v. d1 q21 and pemetrexed 500 mg/sm i.v. 
d1 q21 from February to March 2015. Due to lung progression at the first disease evaluation, second-line 
docetaxel 75 mg/sm i.v. d1 q21 was prescribed, but it had to be immediately interrupted because of an 
infusion reaction with rash and hypotension during the administration of the first cycle. Therefore, the 
treatment was changed to gemcitabine 1250 mg/sm i.v. d1,8 q21, but after only two cycles further lung and 
liver progression was documented at Computed Tomography (CT) scan. Moreover, the patient showed a 
progressive worsening of Performance Status (PS) with dyspnea at rest, cough, severe pain, significant 
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weight loss and fatigue (Karnofsky PS 50%). In June 2015, as soon as immunotherapy became available at 
our Center, third-line nivolumab 3 mg/kg i.v. d1 q14 was prescribed, in spite of the worsening of patient’s 
general conditions. Surprisingly, a significant partial response at all extra-encephalic disease sites and brain 
stability were reported at the first evaluation. Lung and mediastinal lesions underwent further progressive 
response during the following year, while liver metastases completely disappeared and the brain lesion 
remained stable (Figure 1). 
[insert Figure 1] 
In parallel with radiologic response, the patient’s conditions showed extraordinary gradual improvement with 
complete recovery of Karnofsky PS to 100%, in a picture of so-called “Lazarus syndrome”  (Table 1). From 
June 2016 to November 2017, repeated CT and brain magnetic resonance (MRI) scans confirmed disease 
stability. No AEs related to immunotherapy were reported until May 2017, when the patient firstly noticed 
partial alopecia at hair and eyelashes. In the following month, alopecia rapidly progressed and became 
complete, involving all body hair, eyelashes, eyebrows, beard and whiskers (Figure 2). The only concomitant 
symptom was a mild pruritus without rash, lasting for about one month and then spontaneously resolving. 
After the disappearance of pruritus, onycolysis with Beau lines and nail pitting appeared (Figure 2).  
[Insert Figure 2] 
Blood tests to rule out endocrine disorders (e.g. pituitary, adrenal and gonadal hormones) and sella turcica 
MRI were performed, without showing any abnormalities. The patient performed a dermatologic consultation, 
which diagnosed alopecia areata on the basis of physical exam. A diagnostic confirmation was obtained 
through a skin biopsy of the scalp, showing the typical histological pattern of immune-mediated alopecia 
(reduced density of deep hair follicles, aspects of intra-follicular malacia, peri- and intra-follicular lympho-
monocitic infiltrate with prevalence of CD4+ lymphocytes) (Figure 3).  
[Insert Figure 3] 
A steroid therapy with oral prednisone 25 mg q.d. was suggested, but the patient refused it, being afraid of 
toxicity and possible interference with immunotherapy activity. Indeed, the patient was prescribed topic 
steroid therapy for hair (1% hydrocortisone lotion), which was tried for about two months without any benefits 
and then interrupted. At the present, EB is still receiving nivolumab. Complete alopecia persists, but the 




 Alopecia areata is a common dermatologic disease affecting 2-3% of general population. Its most common 
manifestation is a non-itchy, non-scarring hair loss in one or more sharply defined body areas. A rare and 
particularly invalidating variant of this condition is alopecia universalis, inducing a generalized hair loss 
extended to the whole body surface. Nail alterations like pitting, dystrophy and Beau lines (i.e. transverse 
grooves of the nail plate) are frequently associated with the most severe forms of the disease. About one 
third of the patients with alopecia areata undergo spontaneous partial or complete recovery of hair growth 
from 6 to 12 months from the first manifestations of the disease; however, almost all the affected people 
develop recurrent alopecia in the next years and the condition tends to become chronic.4 In the case herein 
described, we interpreted the development of a rapidly progressing form of alopecia universalis as an 
immune-related AE consequent to  nivolumab treatment. Despite the absence of specific features able to 
differentiate the iatrogenic variant of the disease from the idiopathic one, this hypothesis was based on 
different considerations. First of all, the age of onset of the alopecia in this patient is not consistent with the 
typical epidemiology of alopecia areata, which makes its first appearance before the age of 40 in 80% of 
cases and before the age of 20 in 50% of cases. Secondarily, the only predisposing factor for idiopathic 
alopecia areata, in particular for its late-onset forms, is the co-existence of an auto-immune disorder like 
celiac disease, systemic lupus erythematosus and Graves hyperthyroidism.5 Since our patient does not have 
either familiar or personal anamnesis of auto-immunity, no predisposing conditions for alopecia can be 
identified. Thirdly, alopecia areata has a known auto-immune pathogenesis, which probably involves the 
activation of T-lymphocytes against hair follicles as a consequence of aberrant antigen presentation by 
particular Human Leukocytes Antigen (HLA) alleles.6 Nivolumab, like all ICIs, is able to induce a wide range 
of immune-mediated AEs potentially affecting all organs and mimicking the corresponding idiopathic 
conditions. The pathogenesis of immune-mediated toxicity, based on a hyper-activation of T-lymphocytes 
which lose the physiologic inhibitory stop and react against self epitopes, is consistent with the underlining 
mechanism of alopecia areata.7 However, as neither nivolumab discontinuation after the insurgence of the 
toxicity nor drug rechallenge were made, the most convincing evidence supporting a correlation between a 
drug and an adverse event cannot be obtained. At the best of our knowledge, there is only a previous work in 
literature reporting cases of alopecia areata during immunotherapy for cancer.8 Notably, all patients were 
affected by metastatic melanoma or renal cell carcinoma, so this is the very first case reported in a patient 
with NSCLC treated with immunotherapy. Moreover, all the 4 cases described developed skin toxicity in 
concomitance with other systemic adverse events (colitis, transaminitis, itchy rash and elevated hemoglobin, 
diabetes mellitus). On the contrary, our patient is showing an optimal tolerance to nivolumab and alopecia 
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areata still remains the only reported AE. Another aspect to underline in our case is the very late timing of 
insurgence of the skin toxicity, which occurred after almost two years of treatment in a state of absolute well-
being, while all previously reported cases of alopecia appeared within the first year from the beginning of 
immunotherapy. In our patient, the delayed toxicity was associated to an early and prolonged response to 
treatment, with an exceptional clinical benefit. In conclusion, this uncommon case underlines the possibility 
that a wide range of rare toxicities may develop during therapy with ICIs, with atypical features in relation to 
timing of insurgence, target organs, or both. Although alopecia in course of IO is very rare, it can be 
associated to a radical modification of external appearance, with potentially severe psychological distress. 
Therefore, a concise information about the chance of this uncommon event in occasion of the informed 
consent may be advisable. Furthermore, the essential diagnostic management of ICI-related alopecia should 
be standardized, in order to exclude potential underlying etiologies. This overview should include endocrine 
profile of thyroid, gonadal and adrenal function, and brain MRI with focus on pituitary gland. On the other 
hand, the possibility that rare and/or severe toxicities may be associated to the efficacy of treatment still 
remains an open issue and deserves further investigation.9,10 The comprehension of the pathogenesis of 
immune-related AEs and the standardization of their management should be optimized in the next future, 
also in the perspective of the emergence of newer therapeutic strategies whose safety profiles may be 
partially unknown (e.g. anti-LAG, anti-TIM3, anti-GITR).  
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Table 1. Summary of clinical evolution during treatment with nivolumab. 
 Baseline After 4 cycles After 8 cycles After ≥16 cycles 











Cough Yes Yes Yes No 
Hemoptysis Yes No No No 
Asthenia1 G2 G2 G1 No 
Pain2 NRS 8 NRS 6 NRS 4 No 
O2 saturation 
Body weight 
86% in air 
68 kg 
97% in air 
57 kg 
99% in air 
59 kg 
99% in air 
78 kg 
1 according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 
2 according to Numeric Rating Scale for pain (NRS) 
Figure Legends 
Figure 1. Mediastinal and liver disease response at CT scan from May 2015 to April 2016. 
Figure 2. EB’s appearance after the development of alopecia areata (scalp and nails). 
Figure 3. Histology of skin biopsy. 
 
